Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

A prospective study of the effect of pregnancy on CD4 counts and plasma HIV-1 RNA concentrations of antiretroviral-naive HIV-1-infected women.

Heffron R, Donnell D, Kiarie J, Rees H, Ngure K, Mugo N, Were E, Celum C, Baeten JM; Partners in Prevention HSVHIV Transmission Study.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):231-6. doi: 10.1097/QAI.0000000000000013.

2.

Effect of pregnancy on immunological and virological outcomes of women on ART: a prospective cohort study in rural Uganda, 2004-2009.

Mayanja BN, Shafer LA, Van der Paal L, Kyakuwa N, Ndembi N, Hughes P, Maher D, Grosskurth H.

Trop Med Int Health. 2012 Mar;17(3):343-52. doi: 10.1111/j.1365-3156.2011.02921.x. Epub 2011 Dec 30.

3.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

4.

Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers.

Palacios R, Senise J, Vaz M, Diaz R, Castelo A.

HIV Med. 2009 Mar;10(3):157-62. doi: 10.1111/j.1468-1293.2008.00665.x.

5.

Levels and patterns of HIV RNA viral load in untreated pregnant women.

European Collaborative Study, Patel D, Thorne C, Newell ML, Cortina-Borja M.

Int J Infect Dis. 2009 Mar;13(2):266-73. doi: 10.1016/j.ijid.2008.07.004. Epub 2008 Oct 16.

6.

HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

Tamburrini E, Ravizza M, Floridia M, Tibaldi C, Alberico S, Anzidei G, Maccabruni A, Meloni A, Antoni AD, Mori F, Dalzero S, Conservan V, Pinnetti C, Ferrazzi E; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

Antivir Ther. 2008;13(4):519-27.

PMID:
18672530
7.

Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women.

Brown ER, Otieno P, Mbori-Ngacha DA, Farquhar C, Obimbo EM, Nduati R, Overbaugh J, John-Stewart GC.

J Infect Dis. 2009 May 1;199(9):1292-300. doi: 10.1086/597617.

8.

HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods.

Matthews LT, Ribaudo HB, Kaida A, Bennett K, Musinguzi N, Siedner MJ, Kabakyenga J, Hunt PW, Martin JN, Boum Y, Haberer JE, Bangsberg DR.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):399-406. doi: 10.1097/QAI.0000000000000874.

PMID:
26495883
9.

Does pregnancy affect the early response to cART?

Rachas A, Warszawski J, Le Chenadec J, Legeai C, Teglas JP, Goujard C, Rouzioux C, Mandelbrot L, Tubiana R, Meyer L.

AIDS. 2013 Jan 28;27(3):357-67. doi: 10.1097/QAD.0b013e32835ac8bc.

PMID:
23079802
10.

Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women.

Shaheen F, Sison AV, McIntosh L, Mukhtar M, Pomerantz RJ.

J Hum Virol. 1999 May-Jun;2(3):154-66.

PMID:
10413367
11.

Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine.

Ekpini RA, Nkengasong JN, Sibailly T, Maurice C, Adjé C, Monga BB, Roels TH, Greenberg AE, Wiktor SZ.

AIDS. 2002 Mar 8;16(4):625-30.

PMID:
11873007
12.
13.

The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group.

Thea DM, Steketee RW, Pliner V, Bornschlegel K, Brown T, Orloff S, Matheson PB, Abrams EJ, Bamji M, Lambert G, Schoenbaum EA, Thomas PA, Heagarty M, Kalish ML.

AIDS. 1997 Mar 15;11(4):437-44.

PMID:
9084790
14.
15.

HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods.

Matthews LT, Kaida A, Kanters S, Byakwagamd H, Mocello AR, Muzoora C, Kembabazi A, Haberer JE, Martin JN, Bangsberg DR, Hunt PW.

AIDS. 2013 Oct;27 Suppl 1:S105-12. doi: 10.1097/QAD.0000000000000040.

16.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
17.

Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa.

Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, Haas DW, Dooley KE, Martinson NA, Chaisson RE.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):31-7. doi: 10.1097/QAI.0000000000000811.

PMID:
26334739
18.

The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy.

Mnyani CN, McIntyre JA, Myer L.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):260-4. doi: 10.1097/QAI.0b013e318256b651.

PMID:
22487589
19.

HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality.

Otieno PA, Brown ER, Mbori-Ngacha DA, Nduati RW, Farquhar C, Obimbo EM, Bosire RK, Emery S, Overbaugh J, Richardson BA, John-Stewart GC.

J Infect Dis. 2007 Jan 15;195(2):220-9. Epub 2006 Dec 13.

20.

Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.

J Infect Dis. 2007 Oct 1;196(7):1044-52. Epub 2007 Aug 29.

Items per page

Supplemental Content

Write to the Help Desk